Alexandre R Zlotta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8289580/publications.pdf

Version: 2024-02-01

213 papers	10,468 citations	34076 52 h-index	38368 95 g-index
223 all docs	223 docs citations	223 times ranked	9615 citing authors

#	Article	IF	Citations
1	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	0.9	741
2	Recurrence and Progression of Disease in Nonâ€“Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. European Urology, 2009, 56, 430-442.	0.9	584
3	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. European Urology, 2016, 69, 300-310.	0.9	460
4	Radiofrequency Interstitial Tumor Ablation (RITA) Is a Possible New Modality for Treatment of Renal Cancer: Ex Vivo and in Vivo Experience. Journal of Endourology, 1997, 11, 251-258.	1.1	366
5	Extended and Saturation Prostatic Biopsy in the Diagnosis and Characterisation of Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2007, 52, 1309-1322.	0.9	292
6	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. Journal of Clinical Oncology, 2017, 35, 2299-2305.	0.8	241
7	Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience. European Urology, 2015, 68, 1007-1013.	0.9	238
8	4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate Cancer. European Urology, 2000, 38, 706-713.	0.9	227
9	Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology, 2002, 60, 4-9.	0.5	215
10	Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men. Journal of the National Cancer Institute, 2013, 105, 1050-1058.	3.0	208
11	Lymphadenectomy in the Surgical Management of Penile Cancer. European Urology, 2009, 55, 1075-1088.	0.9	201
12	European Association of Urology (EAU) Prognostic Factor Risk Groups for Nonâ€“muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. European Urology, 2021, 79, 480-488.	0.9	198
13	Urine Markers for Detection and Surveillance of Nonâ€“Muscle-Invasive Bladder Cancer. European Urology, 2011, 60, 484-492.	0.9	176
14	â€˜Prostatic evasive anterior tumoursâ€™: the role of magnetic resonance imaging. BJU International, 2010, 105, 1231-1236.	1.3	171
15	An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously) Tj ETQq1 1 0.784314 rgBT /Over	0.9	169
16	PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology, 1999, 54, 517-522.	0.5	152
17	A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. European Urology, 2012, 61, 378-384.	0.9	144
18	Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches. World Journal of Urology, 2003, 20, 360-366.	1.2	142

#	Article	IF	Citations
19	Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Modern Pathology, 2007, 20, 445-459.	2.9	128
20	Immediate Postâ€“Transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Nonâ€“Muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-Evidence Review. European Urology, 2013, 64, 421-430.	0.9	122
21	Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: Early clinical experience. Urology, 1995, 45, 28-33.	0.5	116
22	Transurethral Needle Ablation (TUNA): Safety, Feasibility, and Tolerance of a New Office Procedure for Treatment of Benign Prostatic Hyperplasia. European Urology, 1993, 24, 415-423.	0.9	114
23	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multiâ€institutional study. BJU International, 2011, 108, 24-30.	1.3	111
24	Repeat Prostate Biopsy: Who, How and When?. European Urology, 2002, 42, 93-103.	0.9	109
25	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. European Urology, 2018, 73, 543-557.	0.9	105
26	Long-Term Evaluation of Transurethral Needle Ablation of the Prostate (TUNA) for Treatment of Symptomatic Benign Prostatic Hyperplasia: Clinical Outcome up to Five Years from Three Centers. European Urology, 2003, 44, 89-93.	0.9	102
27	Late Onset of Bladder Urothelial Carcinoma After Kidney Transplantation for End-Stage Aristolochic Acid Nephropathy: A Case Series With 15-Year Follow-up. American Journal of Kidney Diseases, 2008, 51, 471-477.	2.1	99
28	Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU International, 2012, 110, 804-811.	1.3	96
29	Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. European Urology, 2015, 67, 64-70.	0.9	91
30	Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. Journal of Urology, 2015, 193, 1519-1524.	0.2	90
31	Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression after Radical Prostatectomy: A Search Database Study. European Urology, 2006, 49, 757-758.	0.9	87
32	Transperineal radiofrequency interstitial tumor ablation of the prostate: Correlation of magnetic resonance imaging with histopathologic examination. Urology, 1997, 50, 986-993.	0.5	85
33	Patients with Lynch Syndrome Mismatch Repair Gene Mutations Are at Higher Risk for Not Only Upper Tract Urothelial Cancer but Also Bladder Cancer. European Urology, 2013, 63, 379-385.	0.9	85
34	The management of BCG failure in non-muscle-invasive bladder cancer: an update. Canadian Urological Association Journal, 2013, 3, 199.	0.3	85
35	Laparoscopic Partial Nephrectomy with â€œOn-Demandâ€•Clamping Reduces Warm Ischemia Time. European Urology, 2007, 52, 804-810.	0.9	82
36	100 years of Bacillus Calmetteâ€“GuÃ©rin immunotherapy: from cattle to COVID-19. Nature Reviews Urology, 2021, 18, 611-622.	1.9	80

#	Article	IF	Citations
37	Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?. Urology, 1999, 54, 846-852.	0.5	75
38	A feed forward loop enforces YAP/TAZ signaling during tumorigenesis. Nature Communications, 2018, 9, 3510.	5.8	75
39	PSA Progression Following Radical Prostatectomy and Radiation Therapy: New Standards in the New Millenium. European Urology, 2003, 43, 12-27.	0.9	73
40	An artificial neural network to predict the outcome of repeat prostate biopsies. Urology, 2003, 62, 456-460.	0.5	69
41	Treatment Options Available for Bacillus Calmette-GuÃ©rin Failure in Nonâ€“muscle-invasive Bladder Cancer. European Urology, 2012, 62, 1088-1096.	0.9	67
42	CUA guidelines on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal, 2015, 9, 690.	0.3	67
43	Evaluation of Male Sexual Function in Patients with Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) Treated with a Phytotherapeutic Agent (PermixonÂ®), Tamsulosin or Finasteride. European Urology, 2005, 48, 269-276.	0.9	66
44	The Pathologistâ€™s Mean Grade Is Constant and Individualizes the Prognostic Value of Bladder Cancer Grading. European Urology, 2010, 57, 1052-1057.	0.9	65
45	Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives. European Urology, 2013, 63, 1049-1058.	0.9	64
46	Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU International, 2011, 108, E237-E244.	1.3	62
47	What are the immunologically active components of Bacille Calmette-GuÃ©rin in therapy of superficial bladder cancer?. International Journal of Cancer, 2000, 87, 844-852.	2.3	61
48	Prostate cancer prevention. Cancer, 2007, 110, 1889-1899.	2.0	60
49	Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. European Urology, 2014, 66, 619-622.	0.9	57
50	Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. International Journal of Cancer, 2019, 144, 1676-1684.	2.3	57
51	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€. European Urology, 2020, 78, 682-687.	0.9	57
52	Obesity Is Associated with Risk of Progression for Low-risk Prostate Cancers Managed Expectantly. European Urology, 2014, 66, 841-848.	0.9	56
53	A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. Oncotarget, 2016, 7, 57726-57736.	0.8	55
54	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Nonâ€“muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Nonâ€“muscle-invasive Bladder Cancer Guidelines Panel Study. European Urology Oncology, 2021, 4, 182-191.	2.6	54

#	Article	IF	Citations
55	Staging and Staging Errors in Bladder Cancer. European Urology Supplements, 2010, 9, 2-9.	0.1	53
56	Prognostic value of molecular markers, subâ€stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU International, 2012, 110, 1169-1176.	1.3	53
57	Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. British Journal of Cancer, 2016, 114, 207-212.	2.9	53
58	Transurethral Needle Ablation (TUNA): Thermal Gradient Mapping and Comparison of Lesion Size in a Tissue Model and in Patients with Benign Prostatic Hyperplasia. European Urology, 1993, 24, 411-414.	0.9	52
59	A Critical Analysis of Orthotopic Bladder Substitutes in Adult Patients with Bladder Cancer: Is There a Perfect Solution?. European Urology, 2010, 58, 374-383.	0.9	52
60	Impact of 5Î±-Reductase Inhibitors on Men Followed by Active Surveillance for Prostate Cancer. European Urology, 2011, 59, 509-514.	0.9	52
61	Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Nonâ€“Muscle-Invasive Bladder Cancer. European Urology, 2011, 59, 1026-1031.	0.9	51
62	Canadian Urological Association guideline: Muscle-invasive bladder cancer. Canadian Urological Association Journal, 2018, 13, 230-238.	0.3	51
63	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	0.9	49
64	Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer. Clinical Cancer Research, 2008, 14, 7385-7390.	3.2	47
65	Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. Prostate, 2015, 75, 1277-1284.	1.2	47
66	Pathological stage review is indicated in primary pT1 bladder cancer. BJU International, 2010, 106, 206-211.	1.3	46
67	The use of intravesical BCG in urothelial carcinoma of the bladder. Ecancermedicalscience, 2019, 13, 905.	0.6	46
68	Is Seminal Vesicle Ablation Mandatory for All Patients Undergoing Radical Prostatectomy?. European Urology, 2004, 46, 42-49.	0.9	45
69	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics, 2012, 7, 1037-1045.	1.3	42
70	Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. Journal of Urology, 2017, 197, 335-341.	0.2	39
71	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. Journal of Urology, 2017, 197, 75-83.	0.2	39
72	Prostate cancer: a serious disease suitable for prevention. BJU International, 2009, 103, 864-870.	1.3	38

#	Article	IF	Citations
73	Longâ€term followâ€up of T1 highâ€grade bladder cancer after intravesical bacille Calmetteâ€Guérin treatment. BJU International, 2011, 107, 540-546.	1.3	37
74	Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. Modern Pathology, 2015, 28, 695-705.	2.9	37
75	A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy. Clinical Cancer Research, 2017, 23, 1974-1980.	3.2	37
76	The medical management of prostate cancer: a multidisciplinary team approach. BJU International, 2007, 99, 22-27.	1.3	36
77	A Negative Confirmatory Biopsy Among Men on Active Surveillance for Prostate Cancer Does Not Protect Them from Histologic Grade Progression. European Urology, 2014, 66, 406-413.	0.9	36
78	BIOLOGICAL MARKERS IN SUPERFICIAL BLADDER TUMORS AND THEIR PROGNOSTIC SIGNIFICANCE. Urologic Clinics of North America, 2000, 27, 179-189.	0.8	35
79	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. Radiology, 2021, 300, 369-379.	3.6	34
80	The REDUCE trial: chemoprevention in prostate cancer using a dual 5Î±-reductase inhibitor, dutasteride. Expert Review of Anticancer Therapy, 2008, 8, 1073-1079.	1.1	33
81	Clinical significance of the positive surgical margin based upon location, grade, and stage. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 197-204.	0.8	33
82	Next-generation RNA Sequencing of Archival Formalin-fixed Paraffin-embedded Urothelial Bladder Cancer. European Urology, 2014, 66, 982-986.	0.9	33
83	Lean Methodology Improves Efficiency in Outpatient Academic Uro-oncology Clinics. Urology, 2014, 83, 992-998.	0.5	33
84	MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. Radiology, 2021, 298, 695-703.	3.6	33
85	Genderâ€specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU International, 2013, 112, 623-637.	1.3	31
86	The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 386.e7-386.e13.	0.8	31
87	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. Urology, 2016, 93, 77-85.	0.5	31
88	Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer â€“ phase 1 trial. European Radiology, 2018, 28, 4281-4287.	2.3	30
89	Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer. Translational Oncology, 2017, 10, 168-177.	1.7	29
90	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 38-45.	0.9	29

#	Article	IF	Citations
91	Does patient age affect survival after radical cystectomy?. BJU International, 2012, 110, E486-93.	1.3	28
92	Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols. World Journal of Urology, 2013, 31, 161-167.	1.2	28
93	Treatment of bladder cancer in the elderly. Investigative and Clinical Urology, 2016, 57, S26.	1.0	28
94	Urinary/serum prostate-specific antigen ratio: Comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection. Urology, 2005, 65, 533-537.	0.5	27
95	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 440-448.	0.8	27
96	The World Health Organization 1973 classification system for grade is an important prognosticator in T1 nonâ€muscleâ€invasive bladder cancer. BJU International, 2018, 122, 978-985.	1.3	25
97	Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-GuÃ©rin. Urology Annals, 2011, 3, 119.	0.3	23
98	FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 207-213.	1.4	23
99	Development and external validation of a biopsyâ€derived nomogram to predict risk of ipsilateral extraprostatic extension. BJU International, 2017, 120, 76-82.	1.3	23
100	Is one single prostate biopsy helpful for choosing a medical treatment of benign prostatic hyperplasia? a quantitative computerized morphometric study. Urology, 1996, 47, 329-334.	0.5	22
101	Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data. Current Opinion in Urology, 2002, 12, 7-14.	0.9	22
102	Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. BJU International, 2012, 109, 70-76.	1.3	22
103	Obesity Is Associated With Larger Prostate Volume but not With Worse Urinary Symptoms: Analysis of a Large Multiethnic Cohort. Urology, 2014, 83, 81-87.	0.5	22
104	The Importance of Surgeon Characteristics on Impacting Oncologic Outcomes for Patients Undergoing Radical Cystectomy. Journal of Urology, 2014, 192, 714-720.	0.2	22
105	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. Journal of Urology, 2018, 199, 1182-1187.	0.2	22
106	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 110.e1-110.e9.	0.8	22
107	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. BJU International, 2020, 125, 525-530.	1.3	21
108	Limited, Extended, Superextended, Megaextended Pelvic Lymph Node Dissection at the Time of Radical Cystectomy: What Should We Perform?. European Urology, 2012, 61, 243-244.	0.9	20

#	Article	IF	Citations
109	Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis. Clinical Epigenetics, 2016, 8, 32.	1.8	20
110	Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 361.e7-361.e13.	0.8	20
111	Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression. Clinical Epigenetics, 2019, 11, 54.	1.8	20
112	Comparison of laparoscopic radical prostatectomy techniques. Current Urology Reports, 2002, 3, 148-151.	1.0	19
113	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. Journal of Urology, 2016, 196, 1645-1650.	0.2	19
114	Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder â€“ A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. Canadian Urological Association Journal, 2013, 7, 312.	0.3	18
115	Transurethral needle ablation of the prostate. Current Opinion in Urology, 1995, 5, 35-38.	0.9	17
116	Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?. PLoS ONE, 2019, 14, e0216255.	1.1	17
117	Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 850.e9-850.e15.	0.8	17
118	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Canadian Urological Association Journal, 2016, 10, 25.	0.3	17
119	Can survival be prolonged for patients with hormone-resistant prostate cancer?. Lancet, The, 2001, 357, 326-327.	6.3	15
120	Oncologic outcomes following radical prostatectomy in the active surveillance era. Canadian Urological Association Journal, 2013, 7, 475.	0.3	15
121	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nature Communications, 2021, 12, 6248.	5.8	15
122	To Biopsy or Not to Biopsyâ€”Thou Shall Think Twice. European Urology, 2012, 61, 1115-1117.	0.9	14
123	How do I treat and follow my TUNA patients. World Journal of Urology, 2006, 24, 397-404.	1.2	13
124	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	13
125	Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. European Urology Focus, 2021, 7, 1044-1051.	1.6	13
126	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 603.e1-603.e7.	0.8	13

#	Article	IF	Citations
127	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. Canadian Urological Association Journal, 2014, 8, 309.	0.3	12
128	Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?. Canadian Urological Association Journal, 2014, 8, 47.	0.3	11
129	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity scorematched cohort. Canadian Urological Association Journal, 2017, 11, 41.	0.3	11
130	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. European Urology Open Science, 2020, 22, 61-73.	0.2	11
131	The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. Clinical Cancer Research, 2003, 9, 1240-7.	3.2	11
132	Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCare^{Bladder}): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records. Journal of the American Medical Informatics Association: JAMIA, 2011, 18, 835-841.	2.2	10
133	Molecular Characterization of Bladder Cancer. Current Urology Reports, 2018, 19, 107.	1.0	10
134	Lynch Syndrome in Urologic Malignancies â€“ What Does the Urologist Need to Know?. Urology, 2019, 134, 24-31.	0.5	10
135	Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach. European Urology Focus, 2021, 7, 582-588.	1.6	10
136	Hormone Therapy: Improving Therapy Decisions and Monitoring. European Urology Supplements, 2006, 5, 369-376.	0.1	9
137	Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression?. Urology Annals, 2010, 2, 58.	0.3	9
138	An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. Journal of Urology, 2016, 195, 307-312.	0.2	9
139	An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 39.e1-39.e9.	0.8	9
140	A Prospective Randomized Controlled Trial of Irrigation â€œBag Squeezeâ€•to Manage Pain for Patients Undergoing Flexible Cystoscopy. Journal of Urology, 2020, 204, 1012-1018.	0.2	9
141	Health-related quality of life in robotic versus open radical prostatectomy. Canadian Urological Association Journal, 2015, 9, 179.	0.3	9
142	Prognosis of T1G3 Tumors: Clinical Factors. European Urology Supplements, 2004, 3, 73-78.	0.1	8
143	Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. Therapeutics and Clinical Risk Management, 2008, Volume 4, 11-18.	0.9	8
144	Optimal timing of radical cystectomy in T1 high-grade bladder cancer. Expert Review of Anticancer Therapy, 2010, 10, 1891-1902.	1.1	8

#	Article	IF	Citations
145	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. International Journal of Radiation Oncology Biology Physics, 2019, 104, 61-66.	0.4	8
146	Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer â€“ Abridged version. Canadian Urological Association Journal, 2021, 15, 230-9.	0.3	8
147	Trimodal therapy in muscle invasive bladder cancer management. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 650-662.	3.9	8
148	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. European Radiology, 2022, 32, 7544-7554.	2.3	8
149	Neoadjuvant and adjuvant hormone therapy for prostate cancer. World Journal of Urology, 2000, 18, 179-182.	1.2	7
150	Canadian Consensus Conference: The FDA decision on the use of 5ARIs. Canadian Urological Association Journal, 2012, 6, 83-88.	0.3	7
151	Re: Genome Sequencing Identifies a Basis for Everolimus Sensitivity. European Urology, 2013, 64, 516.	0.9	7
152	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. Bladder Cancer, 2016, 2, 263-272.	0.2	7
153	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 240.e13-240.e20.	0.8	7
154	Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patientsâ€™ and urologic oncologistsâ€™ perspectives. Canadian Urological Association Journal, 2018, 12, E210-8.	0.3	7
155	Statin use and time to progression in men on active surveillance for prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 509-515.	2.0	7
156	Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal, 2021, 15, E424-E460.	0.3	7
157	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castrationâ€resistant prostate cancer treated with Radiumâ€223. Cancer Medicine, 2021, 10, 5775-5782.	1.3	7
158	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. Journal of Urology, 2020, 204, 476-482.	0.2	7
159	A semi-supervised learning approach for bladder cancer grading. Machine Learning With Applications, 2022, 9, 100347.	3.0	7
160	Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. BJU International, 2005, 95, 285-290.	1.3	6
161	Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments. Expert Opinion on Pharmacotherapy, 2006, 7, 1685-1699.	0.9	6
162	What is the future of virtual cystoscopy in urology?. Canadian Urological Association Journal, 2011, 5, 38-39.	0.3	6

#	Article	IF	Citations
163	Demographic analysis of randomized controlled trials in bladder cancer. BJU International, 2013, 111, 419-426.	1.3	6
164	Regular Transition Zone Biopsy during Active Surveillance for Prostate Cancer May Improve Detection of Pathological Progression. Journal of Urology, 2014, 192, 1088-1093.	0.2	6
165	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. Canadian Urological Association Journal, 2016, 10, 424.	0.3	6
166	Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A population-based analysis. Canadian Urological Association Journal, 2018, 12, 203-10.	0.3	6
167	Quality of Life after Radical Prostatectomy: How to Preserve Potency?. European Urology Supplements, 2005, 4, 2-7.	0.1	5
168	Comprehensive Imaging and Surgical Review of Urinary Diversions: What the Radiologist Needs to Know. Current Problems in Diagnostic Radiology, 2019, 48, 161-171.	0.6	5
169	Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population Based Study. Journal of Urology, 2019, 202, 319-325.	0.2	5
170	Urothelial Bladder Cancer Urinary Biomarkers. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2014, 25, 99-114.	0.7	5
171	The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use. Clinical Therapeutics, 2005, 27, 273-285.	1.1	4
172	Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-based, Diagnostic Study. European Urology, 2020, 78, 290-291.	0.9	4
173	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. Prostate, 2021, 81, 286-294.	1.2	4
174	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. PLoS ONE, 2021, 16, e0259272.	1.1	4
175	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Nonâ€“muscle-invasive Bladder Cancer Spectrum. European Urology Focus, 2022, , .	1.6	4
176	When and How to Treat Superficial and Muscle-Invasive Bladder Cancer. European Urology, 2007, 52, 1554-1557.	0.9	3
177	Focal Therapy Will Be the Future Treatment Modality: The Motion â€œConâ€• European Urology Supplements, 2009, 8, 433-438.	0.1	3
178	Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologistâ€™s practice patterns. International Urology and Nephrology, 2011, 43, 31-37.	0.6	3
179	A novel predictor of clinical progression in patients on active surveillance for prostate cancer. Canadian Urological Association Journal, 2018, 13, 250-255.	0.3	3
180	Further Evidence of Differences in Prostate Cancer Biomarkers Between Caucasian and Asian Men. European Urology, 2019, 75, 562-563.	0.9	3

#	Article	IF	Citations
181	Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients. Journal of Molecular Diagnostics, 2020, 22, 30-39.	1.2	3
182	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2020, 14, 404-410.	0.3	3
183	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 835.e1-835.e7.	0.8	3
184	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. Canadian Urological Association Journal, 2021, 16, .	0.3	3
185	Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. Clinical Genitourinary Cancer, 2022, 20, e217-e226.	0.9	3
186	Prevalence of prostate cancer across the globe: what can autopsy studies teach us about this peculiar disease?. Archivos Espanoles De Urologia, 2014, 67, 400-8.	0.1	3
187	Computerised Assessment of Maximum Urinary Flow: an Efficient, Consistent and Valid Approach. European Urology, 2002, 41, 206-213.	0.9	2
188	The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma. BJU International, 2009, 104, 1641-1645.	1.3	2
189	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. Urology, 2014, 84, 1073-1080.	0.5	2
190	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 604.e17-604.e24.	0.8	2
191	What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?. Canadian Urological Association Journal, 2017, 11, 118.	0.3	2
192	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. Journal of Urology, 2018, 200, 1056-1061.	0.2	2
193	Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening. European Urology, 2020, 78, 927-929.	0.9	2
194	Laparoscopic partial bladder resection for bladder endometriosis. Gynaecological Endoscopy, 1999, 8, 11-15.	0.3	1
195	Modified specimen retrieval facilitates urethro-vesical anastomosis in laparoscopic radical prostatectomy. BJU International, 2005, 95, 447-449.	1.3	1
196	Auto-Antibody Signatures in Prostate Cancer. European Urology, 2006, 49, 410-411.	0.9	1
197	Random Biopsies in Bladder Tumors: In Most Cases, You Shall Not!. European Urology, 2006, 50, 186-193.	0.9	1
198	Immediate versus deferred androgen-deprivation therapy for prostate cancer: the jury is still out. Nature Reviews Urology, 2006, 3, 474-475.	1.4	1

#	Article	IF	Citations
199	Chemoprevention of prostate cancer: is there evidence from clinical trials?. Clinical Investigation, 2011, 1, 1257-1268.	0.0	1
200	Weighing the data on diet and prostate cancer. Canadian Urological Association Journal, 2013, 2, 516.	0.3	1
201	Are there differences among Bacillus Calmette-GuÃ©rin (BCG) strains regarding their clinical efficacy in the treatment of non-muscle invasive bladder cancer? The jury is still out but the answer is likely no. Canadian Urological Association Journal, 2019, 14, E54-E56.	0.3	1
202	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434â€“5. European Urology, 2020, 77, 436-438.	0.9	1
203	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (¹⁸F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. Journal of Clinical Oncology, 2020, 38, 5553-5553.	0.8	1
204	Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study.. Journal of Clinical Oncology, 2012, 30, 30-30.	0.8	1
205	Re: A Sequence Variant at 4p16.3 Confers Susceptibility to Urinary Bladder Cancer. European Urology, 2010, 58, 943-944.	0.9	0
206	Positive Surgical Margins: Race or Surgeon?. European Urology, 2015, 67, 458-459.	0.9	0
207	Whatâ€™s new bladder cancer research?. Canadian Urological Association Journal, 2016, 10, 134.	0.3	0
208	Editorial Comment. Journal of Urology, 2018, 199, 967-967.	0.2	0
209	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. Canadian Urological Association Journal, 2019, 13, E292-E299.	0.3	0
210	Novel use of an old compound? Urologistâ€ed Bacille Calmetteâ€“GuÃ©rin vaccine trials in the prevention of coronavirus disease 2019. BJU International, 2021, 127, 35-36.	1.3	0
211	Association of tumor hypoxia with lower survival after radiotherapy for muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2012, 30, 292-292.	0.8	0
212	Reply by Authors. Journal of Urology, 2019, 202, 325-325.	0.2	0
213	The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0